A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial - Gisslinger, H; Buxhofer-Ausch, V; Hodisch, J (Br J Haematol, 2019)